Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS | ($2.8) | ($2.0) | ($1.1) | ($2.2) | ($0.6) | ($1.1) | ($1.0) | ($1.4) | ($2.1) | ($1.5) | ($4.9) | ($3.5) | ($4.8) | ($5.4) | ($7.6) | ($8.1) | ($7.5) | ($7.2) | ($9.3) | ($3.5) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Alnylam Pharmaceuticals, Inc.'s last 12-month EPS is ($2.6), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Alnylam Pharmaceuticals, Inc.'s EPS growth was (36.3%). The average annual EPS growth rates for Alnylam Pharmaceuticals, Inc. have been (29.7%) over the past three years, (19.5%) over the past five years.
Over the last year, Alnylam Pharmaceuticals, Inc.'s EPS growth was (36.3%), which is lower than industry growth of (0.2%). It indicates that Alnylam Pharmaceuticals, Inc.'s EPS growth is Bad.